Literature DB >> 19141577

Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome.

Jin Yeong Kim1, Haengseok Song, Hyunjoo Kim, Hee Jung Kang, Jin Hyun Jun, Sung Ran Hong, Mi Kyoung Koong, In Sun Kim.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by chronic oligo/anovulation, hyperandrogenemia, infertility, and metabolic alterations related to insulin resistance. These abnormalities in PCOS may have complex effects on pathophysiology of the endometrium, contributing to infertility and endometrial disorders.
OBJECTIVE: The objective of this study was to examine dysregulated signaling pathways in the endometrium of patients with PCOS (PCOSE) by analyzing expression profiles with a pathway-oriented method.
DESIGN: Microarrays, RT-PCR, laser capture microdissection, and immunohistochemistry were performed with endometrial tissues.
SETTING: This study was performed at a university hospital laboratory. PATIENTS: This study comprised 12 regularly cycling women and 12 PCOS patients. MAIN OUTCOME MEASURE: Dysregulated signaling pathways in PCOSE were identified as a gene set.
RESULTS: Hierarchical clustering revealed distinct expression profiles for PCOSE and the endometrium of normal cycling women. Gene sets associated with androgen signaling were not enriched in PCOSE, although they affect ovarian physiology of PCOS patients. Several biological pathways including cell cycle, apoptosis, glycolysis, and integrin-Rho-cytoskeleton network were aberrantly down-regulated in PCOSE. Expression of genes constituting these gene sets enriched in normal cycling women was systemically down-regulated in PCOSE. Laser capture microdissection-coupled real-time RT-PCR and immunohistochemistry further demonstrated that cell proliferation in the stroma, but not the epithelium, is significantly reduced in PCOSE.
CONCLUSIONS: Systemic down-regulation of various signaling pathways in PCOSE with extremely prolonged proliferative phase provides insight into the abnormal phenotypes that reflect pathophysiology of PCOS in the endometrium, possibly leading to increased risks of endometrial disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141577      PMCID: PMC2682468          DOI: 10.1210/jc.2008-1612

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients.

Authors:  M Ludwig; D F Finas; S al-Hasani; K Diedrich; O Ortmann
Journal:  Hum Reprod       Date:  1999-02       Impact factor: 6.918

2.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield; M K Cavaghan; J Imperial
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

3.  Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.

Authors:  M A Okon; S M Laird; E M Tuckerman; T C Li
Journal:  Fertil Steril       Date:  1998-04       Impact factor: 7.329

Review 4.  Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women.

Authors:  E Carmina; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

5.  Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

Authors:  G Saccani Jotti; S R Johnston; J Salter; S Detre; M Dowsett
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

6.  Polycystic ovaries are a common finding in untreated female to male transsexuals.

Authors:  A H Balen; M E Schachter; D Montgomery; R W Reid; H S Jacobs
Journal:  Clin Endocrinol (Oxf)       Date:  1993-03       Impact factor: 3.478

7.  17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.

Authors:  T D Pache; W C Hop; F H de Jong; R A Leerentveld; H van Geldorp; T M Van de Kamp; L J Gooren; B C Fauser
Journal:  Clin Endocrinol (Oxf)       Date:  1992-06       Impact factor: 3.478

Review 8.  Reproductive health and polycystic ovary syndrome.

Authors:  M Gibson
Journal:  Am J Med       Date:  1995-01-16       Impact factor: 4.965

9.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.

Authors:  E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

10.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

Authors:  R S Legro; A R Kunselman; W C Dodson; A Dunaif
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

View more
  24 in total

1.  Heirarchical clustering and beyond in PCOS endometrium: brave new world.

Authors:  Richard S Legro; Jan M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2009-04       Impact factor: 5.958

2.  Endometrial progesterone receptor isoforms in women with polycystic ovary syndrome.

Authors:  Min Hu; Juan Li; Yuehui Zhang; Xin Li; Mats Brännström; Linus R Shao; Håkan Billig
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

3.  Warburg-like Glycolysis and Lactate Shuttle in Mouse Decidua during Early Pregnancy.

Authors:  Ru-Juan Zuo; Xiao-Wei Gu; Qian-Rong Qi; Tong-Song Wang; Xu-Yu Zhao; Ji-Long Liu; Zeng-Ming Yang
Journal:  J Biol Chem       Date:  2015-07-15       Impact factor: 5.157

Review 4.  Immunometabolism, pregnancy, and nutrition.

Authors:  Kristin Thiele; Lianghui Diao; Petra Clara Arck
Journal:  Semin Immunopathol       Date:  2017-10-25       Impact factor: 9.623

5.  Inflammatory Stimuli Trigger Increased Androgen Production and Shifts in Gene Expression in Theca-Interstitial Cells.

Authors:  Chelsea W Fox; Lingzhi Zhang; Abhishek Sohni; Manuel Doblado; Miles F Wilkinson; R Jeffrey Chang; Antoni J Duleba
Journal:  Endocrinology       Date:  2019-12-01       Impact factor: 4.736

Review 6.  Basic aspects of endometrial receptivity in PCOS patients.

Authors:  Amruta D S Pathare; Indira Hinduja; Roshani C Mahadik
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

7.  O-GlcNAc modification mediates aquaporin 3 to coordinate endometrial cell glycolysis and affects embryo implantation.

Authors:  Hongshuo Zhang; Jia Qi; Jingyuan Pei; Man Zhang; Yuhong Shang; Zhen Li; Yufei Wang; Jinqiu Guo; Kaiqi Sun; Jianhui Fan; Linlin Sui; Yuefei Xu; Li Kong; Ying Kong
Journal:  J Adv Res       Date:  2021-06-30       Impact factor: 12.822

8.  In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis.

Authors:  Elaine Marshall; Jacqueline Lowrey; Sheila MacPherson; Jacqueline A Maybin; Frances Collins; Hilary O D Critchley; Philippa T K Saunders
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

9.  Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids.

Authors:  Dessie Salilew-Wondim; Qi Wang; Dawit Tesfaye; Karl Schellander; Michael Hoelker; Md Munir Hossain; Benjamin K Tsang
Journal:  J Ovarian Res       Date:  2015-04-13       Impact factor: 4.234

10.  Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling.

Authors:  Chen-Wei Lan; Mei-Jou Chen; Kang-Yu Tai; Danny Cw Yu; Yu-Chieh Yang; Pey-Shynan Jan; Yu-Shih Yang; Hsin-Fu Chen; Hong-Nerng Ho
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.